Prognosis
Long-Dreaded Amazon Threat to Drug Middlemen Draws Closer
- Benefit-manager stocks steady after sliding on new venture
- Brash effort looks to reorder health system to contain costs
This article is for subscribers only.
A day that prescription-drug middlemen had long feared finally arrived.
The industry awoke to the news Tuesday that Amazon.com Inc. was joining with Berkshire Hathaway Inc. and JPMorgan Chase & Co. to form a new health-care business, in an attempt by three of the world’s best-known companies to contain the spiraling cost of keeping their U.S. workers healthy.